Depixus
Company

Last deal

$27.6M
Local Amount - EUR 30.6M

Amount

Series A

Stage

15.12.2021

Date

4

all rounds

$31M

Total amount

General

About Company
Depixus develops a technology that extracts genetic and epigenetic information from single molecules of DNA and RNA.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2012

Number of employees

Company Type

For Profit

Last funding type

Series A

IPO status

Private

Description

Their technology, SIMDEQ, allows for quick and easy analysis of a full genome or genomic region on a single platform. Users can specify the level of sequence and epigenetic detail required, enabling doctors to obtain fast results with low operating costs. Depixus aims to provide a disruptive and cost-effective solution for extracting sequence and epigenetic information from long individual molecules of DNA and RNA, going beyond decoding the static genetic code to reveal the dynamics of the genome that control health and disease.
Contacts

Social url